Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02228798 · ClinicalTrials.gov registry record
Perioperative Anticoagulant Use for Surgery Evaluation Study
A clinical trial, sponsored by McMaster University.
- Completed
- Registry status
- 3,135
- Enrollment target
NCT02228798 is a clinical trial that has completed, run by McMaster University. The registered enrollment target is 3,135 participants.
The verdict
NCT02228798 has completed, sponsored by McMaster University.
- COMPLETED
- Registry status
- 3,135 participants
- Enrollment target
Study Summary
The aim of the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study, is to establish a safe, standardized protocol for the perioperative management of patients with atrial fibrillation (AF) who are receiving a novel oral anticoagulant (DOAC) drug, either dabigatran, rivaroxaban or apixaban, and require an elective surgery/procedure.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,135 participants |
| Start Date | 2014-08-01 |
| Est. Completion | 2018-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02228798
The ClinicalTrials.gov registry entry for NCT02228798 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is McMaster University, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02228798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02228798 about?
NCT02228798 is a clinical study titled "Perioperative Anticoagulant Use for Surgery Evaluation Study". The aim of the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study, is to establish a safe, standardized protocol for the perioperative management of patients with atrial fibrillation (AF) who are receiving a novel oral anticoagulant (DOAC) drug, either dabigatran, rivaroxaban or ap...
What is the current status of trial NCT02228798?
This trial is currently completed. The enrollment target is 3,135 participants. The study started on 2014-08-01. Estimated completion is 2018-08-31.
Who is sponsoring clinical trial NCT02228798?
This trial is sponsored by McMaster University, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.